{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-26-008465","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2026-06-03T20:17:06+00:00","discovered_at":"2026-06-03T20:18:01.285511+00:00","generated_at":"2026-06-03T20:48:20.642118+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ADC Therapeutics: LOTIS-5 Phase 3 meets PFS endpoint; sBLA submission planned Q4 2026","bullets":["PFS HR=0.73 (p=0.008); median PFS 6.1 mo ZYNLONTA+ritux vs 4.7 mo R-GemOx.","ORR 58.1% vs 45.2%; CR 39.5% vs 26.7%; median DoCR 16.8 vs 12.3 mo.","Grade 5 TEAEs higher in test arm (13.2% vs 4.6%); majority in patients ≥75 years.","Plans pre-sBLA meeting with FDA in August; sBLA submission expected Q4 2026.","Company will evaluate value-maximizing alternatives, including cost reduction initiatives."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-26-008465","json":"https://secwatch.observer/filing/0000950103-26-008465.json","markdown":"https://secwatch.observer/filing/0000950103-26-008465.md","text":"https://secwatch.observer/filing/0000950103-26-008465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008465/0000950103-26-008465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008465/dp247928_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T20:48:20.642118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}